MOTS-c Dosing: 1mg Daily, 5-On/2-Off Protocol

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that activates AMPK, enhancing glucose metabolism, insulin sensitivity, and fatty acid oxidation. It's frequently described as an "exercise mimetic" — though it complements exercise rather than replacing it.

No MOTS-c formulation is FDA-approved. All protocols below are derived from published research and community experience. This is not medical advice.

Quick Reference: Standard Protocol

For a comparison of MOTS-c vs SS-31 (Elamipretide), see our SS-31 vs MOTS-c comparison.

Cycling Details

The standard cycle is 1 mg daily (5 on / 2 off) for 8 weeks, then 8 weeks off. The rationale is AMPK-mTOR balance — chronic AMPK activation can suppress mTOR-mediated protein synthesis, so cycling allows the body to alternate between metabolic optimization (AMPK-dominant) and growth/repair (mTOR-dominant) phases.

Morning dosing aligns with natural metabolic rhythms and complements exercise — Lai et al. (2021) showed that exercise itself induces endogenous MOTS-c expression, and intermittent dosing (3x/week) was sufficient to improve physical capacity in aged mice (Lai et al., 2021).

Enhanced Metabolic Protocol (Community)

For individuals targeting metabolic improvement or body composition, community protocols use higher doses based on the original animal research:

5 mg is derived from animal studies using 5 mg/kg IP (which does not translate linearly to humans). Best combined with structured exercise. Monitor fasting insulin, HOMA-IR, lipid panel, and body composition.

Routes of Administration

Subcutaneous injection is the standard route — abdomen, thigh, or love handles. Inject with a 29-31 gauge insulin syringe. Volume is typically 0.2 mL for the standard 1 mg dose.

No oral route — MOTS-c is a peptide that would be destroyed by digestive enzymes.

Reconstitution Quick Reference

Math: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. For 1 mg: 1 / 5 = 0.2 mL = 20 units.

Swirl gently — do not shake. Refrigerate after mixing, use within 28 days. Store unreconstituted vials at -20 C. For step-by-step instructions, see the full MOTS-c Reconstitution Guide.

Where These Numbers Come From

MOTS-c was first identified by Changhan Lee and colleagues in 2015 as a mitochondrial-encoded signaling peptide (Lee et al., 2015). The key findings driving current protocols:

AMPK activation mechanism: MOTS-c targets the methionine-folate cycle, raising cellular AICAR concentrations that activate AMPK. Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus to regulate adaptive gene expression (Kim et al., 2018).

Late-life efficacy: MOTS-c treatment initiated at the mouse equivalent of ~70 human years improved physical capacity and healthspan with intermittent dosing (3x/week) (Lai et al., 2021).

Exercise mimetic context: MOTS-c activates overlapping pathways with exercise (AMPK, glucose uptake, fat oxidation) but does not replicate cardiovascular adaptation, bone loading, or neuromuscular development. It's best understood as a metabolic supplement to exercise, not a replacement.

Stacking Protocols

MOTS-c and SS-31 work through completely different mechanisms — MOTS-c signals via AMPK while SS-31 physically stabilizes cardiolipin. See our SS-31 vs MOTS-c comparison for a detailed breakdown.

Side Effects & Safety

• Injection site reactions — redness, mild pain, or swelling (more common with larger volumes)
• Transient hypoglycemia-like symptoms — light-headedness or hunger if dosed fasted, reflecting glucose-lowering activity
• Mild GI discomfort — nausea or stomach upset, typically first few days only
• Mild flushing or warmth — occasional, transient
• AMPK-mTOR trade-off — chronic AMPK activation may suppress muscle protein synthesis (rationale for cycling)
• Drug interaction: metformin — both activate AMPK; additive glucose-lowering possible. Monitor blood glucose.
• Contraindicated: Type 1 diabetes (unpredictable hypoglycemia), pregnancy/breastfeeding (no safety data)

Frequently Asked Questions

What is the standard MOTS-c dose?

1 mg subcutaneously in the morning, 5 days on / 2 days off, 8 weeks on / 8 weeks off. Reconstitute a 10 mg vial with 2 mL BAC water (5 mg/mL) and draw 20 units per dose.

Why is morning dosing recommended for MOTS-c?

MOTS-c activates AMPK and enhances glucose uptake — metabolic effects that align best with morning metabolic activity and the period when physical activity typically occurs, complementing MOTS-c's exercise-mimetic properties.

How do I reconstitute MOTS-c?

Add 2 mL of bacteriostatic water to a 10 mg vial. Concentration is 5 mg/mL. A 1 mg dose = 20 units on an insulin syringe. Store refrigerated, use within 28 days.

How long should a MOTS-c cycle last?

8 weeks on, 8 weeks off. Cycling prevents chronic AMPK activation from suppressing mTOR-mediated protein synthesis.

Can MOTS-c replace exercise?

No. While MOTS-c activates similar metabolic pathways (AMPK, glucose uptake, fat oxidation), it does not replicate cardiovascular adaptation, neuromuscular development, bone loading, or the psychological benefits of exercise. Research suggests MOTS-c and exercise are synergistic.

How does MOTS-c compare to SS-31?

They target mitochondria through completely different mechanisms. MOTS-c activates AMPK and regulates metabolism systemically. SS-31 binds cardiolipin in the inner mitochondrial membrane to stabilize electron transport. See our SS-31 vs MOTS-c comparison for details.

Related Guides

• SS-31 vs MOTS-c — Head-to-head comparison of the two major mitochondrial peptides
• SS-31 (Elamipretide) Dosing Guide — Cardiolipin-targeting mitochondrial peptide
• NAD+ Dosing Guide — NAD+ protocols to complement mitochondrial stacks
• MOTS-c Reconstitution Guide — Step-by-step mixing and dilution charts
• MOTS-c Bloodwork Guide — What labs to track and optimal ranges
• Peptide Stacking Guide — How to combine peptides for complementary effects
• Calculate Your MOTS-c Cycle Cost — estimate vials needed and total cost for your protocol

References

For educational and research purposes only. This is not medical advice. MOTS-c is not FDA-approved for any indication.